Litcius/Paper detail

Patient-centred outcomes and effect of disease progression on health status in patients with newly diagnosed advanced ovarian cancer and a BRCA mutation receiving maintenance olaparib or placebo (SOLO1): a randomised, phase 3 trial

Michael Friedländer, Kathleen N. Moore, Nicoletta Colombo, Giovanni Scambia, Byoung‐Gie Kim, Ana Oaknin, Alla Lisyanskaya, Gabe S. Sonke, Charlie Gourley, Susana Banerjee, Amit M. Oza, Antonio González-Martı́n, Carol Aghajanian, William H. Bradley, Joyce F. Liu, Cara Mathews, Frédèric Selle, Alain Lortholary, Elizabeth Lowe, Robert Hettle, Emuella Flood, Elena Parkhomenko, Paul DiSilvestro

2021The Lancet Oncology55 citationsDOI

Topics & Concepts

MedicineBRCA mutationInternal medicineOvarian cancerClinical endpointOncologyOlaparibPlaceboQuality of life (healthcare)CancerResponse Evaluation Criteria in Solid TumorsProgression-free survivalClinical trialProgressive diseaseChemotherapyPathologyAlternative medicineBiochemistryGenePolymerasePoly ADP ribose polymeraseChemistryNursingPARP inhibition in cancer therapyOvarian cancer diagnosis and treatmentBRCA gene mutations in cancer
Patient-centred outcomes and effect of disease progression on health status in patients with newly diagnosed advanced ovarian cancer and a BRCA mutation receiving maintenance olaparib or placebo (SOLO1): a randomised, phase 3 trial | Litcius